Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

A. N. Niemeijer, D. Leung, M. C. Huisman, I. Bahce, O. S. Hoekstra, G. A.M.S. van Dongen, R. Boellaard, S. Du, W. Hayes, R. Smith, A. D. Windhorst, N. H. Hendrikse, A. Poot, D. J. Vugts, E. Thunnissen, P. Morin, D. Lipovsek, D. J. Donnelly, S. J. Bonacorsi, L. M. VelasquezT. D. de Gruijl, E. F. Smit, A. J. de Langen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

PD-L1 immunohistochemistry correlates only moderately with patient survival and response to PD-(L)1 treatment. Heterogeneity of tumor PD-L1 expression might limit the predictive value of small biopsies. Here we show that tumor PD-L1 and PD-1 expression can be quantified non-invasively using PET-CT in patients with non-small-cell lung cancer. Whole body PD-(L)1 PET-CT reveals significant tumor tracer uptake heterogeneity both between patients, as well as within patients between different tumor lesions.

Original languageEnglish
Article number4664
JournalNature Communications
Volume9
Issue number1
DOIs
Publication statusPublished - 1 Dec 2018

Cite this